COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris Therapeutics, Inc. (OSIR), the leading stem cell company focused on developing and marketing products in orthopedics, sports medicine and wound care, announced today that data, published in Ostomy Wound Management, shows that the use of Grafix® on a variety of chronic wounds resulted in an overall closure rate of 76% by 12 weeks, including 68% of Venous Leg Ulcers (VLUs) and 85% of Diabetic Foot Ulcers (DFUs) treated. The publication is available in the December 2013 issue of Ostomy Wound Management and on its website.
“The overall healing rate of 76% among recalcitrant wounds demonstrates the profound effect Grafix had on my patients,” said Dr. Matthew Regulski, lead author and Medical Director of the Wound Institute of New Jersey. “Many of these patients had failed multiple advanced treatments and were without other options. The ability to not only close these wounds quickly but keep them closed, with no wound recurrence out to almost 2 years, saved these patients from additional morbidities associated with non-healing chronic wounds such as infection, hospitalization, and even amputation.”
The study evaluated the use of Grafix in 67 chronic wounds (66 patients), including 34 VLUs, 27 DFUs, and 6 other chronic wounds. Patients evaluated in this study had a mean wound duration prior to treatment of 38 weeks indicating the truly refractory nature of these wounds. Additionally, 75% of the patients in this study had failed at least one advanced wound therapy prior to receiving Grafix. Among the patients that closed, the mean time to closure was 5.8 weeks with an average of 3.2 applications. Additionally, no Grafix-related adverse events were reported and no wound recurrences were observed among patients that closed with a mean follow-up of 20.4 months.
“This data is a nice compliment to our multi-center, randomized, controlled trial in DFUs, which showed that Grafix had overwhelming efficacy with a relative effect of 191% when compared to control treatment,” said Dr. Doug Jacobstein, Senior Director of Medical Affairs at Osiris. “We are pleased to offer patients, including those with limited treatment options, a novel, cellular treatment with conclusive clinical evidence. More importantly, healing wounds quickly with fewer treatments is cost-effective, and better for patients, physicians, and payors.”
Grafix is a human cellular matrix containing living stem cells for acute and chronic wounds. It is a flexible, conforming membrane that provides a high quality source of living MSCs and growth factors directly to the site of the wound. Grafix is produced by BioSmartTM Intelligent Tissue Processing of human placental membrane. The manufacturing process maintains the integrity of the extracellular matrix, the viability of the neonatal MSCs, and the biologically active growth factors.
About Osiris Therapeutics
Osiris Therapeutics, Inc. is the leading stem cell company, having developed the world’s first approved stem cell drug, remestemcel-L for graft versus host disease. Osiris’ products include Grafix and Ovation® for acute and chronic wounds, Cartiform®, a viable cartilage mesh for cartilage repair and the latest addition to Osiris’ line of products, OvationOS™, a viable bone matrix. Osiris is a fully integrated company with capabilities in research, development, manufacturing and distribution. Osiris has developed an extensive intellectual property portfolio to protect the company's technology and commercial interests.
Osiris, Grafix, Ovation and Cartiform are registered trademarks of Osiris Therapeutics, Inc. More information can be found on the company's website, www.Osiris.com. (OSIR-G)
This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as "anticipate," "believe," "continue," "ongoing," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project" or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding any of the following: our product development efforts; our clinical trials and anticipated regulatory requirements, and our ability to successfully navigate these requirements; the success of our product candidates in development; status of the regulatory process for our product and product candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy for marketed Biosurgery products (including Grafix, Ovation, OvationOS and Cartiform) and Biosurgery products under development; our cash needs; patents, trademarks and other proprietary rights; the safety and ability of our products and potential products to address medical needs; our ability to supply a sufficient amount of our marketed products or product candidates and, if approved or otherwise commercially available products, to meet demand; our costs to comply with governmental regulations; our plans for sales and marketing; our plans regarding facilities; types of regulatory frameworks we expect will be applicable to our products and potential products; and results of our scientific research. Additional risks and uncertainties related to the sale of our ceMSC assets and the related transactions contemplated by the Purchase Agreement with Mesoblast include typical business transactional risks, the risk of changing relationships with customers, suppliers or employees, the risk associated with the disposition of our ceMSC assets and the increased relative dependence on and importance of our other business including our Biosurgery business, the risk that we may not be able to fully benefit from the transactions through milestone payments or royalties, payment risks, including the risk associated with receipt of equity as consideration, in lieu of cash, and the risk of dependence on others to achieve results upon which milestone or royalty payments to us are conditioned. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled "Risk Factors" in our Annual Report on Form 10-K and other Periodic Reports filed on Form 10-Q, with the United States Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.
- Health Care Industry
- Osiris Therapeutics
- chronic wounds
Aziz Ahmad, 443-545-1834